Xencor, Inc Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Xencor, Inc (XNCR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 623.24 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-05
- Xencor, Inc share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 262.99K shares.
- Xencor, Inc share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 360.25K shares.
- Xencor, Inc share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 885.46K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|
| 2026-06-30 | 262.99K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 623.24K shares 10-Q · filed 2026-08-05 | |
| 2026-03-31 | 360.25K shares 10-Q · filed 2026-05-06 | ||
| 2025-12-31 | 885.46K shares 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |